# Rituximab Plus Interleukin-2 in Treating Patients With Lymphoma

> **NCT00003356** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of Rochester** · enrollment: 58 (estimated)

## Conditions studied

- Lymphoma

## Interventions

- **BIOLOGICAL:** aldesleukin
- **BIOLOGICAL:** rituximab

## Key facts

- **NCT ID:** NCT00003356
- **Lead sponsor:** University of Rochester
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1997-11
- **Primary completion:** 2002-05
- **Final completion:** 2002-05
- **Target enrollment:** 58 (ESTIMATED)
- **Last updated:** 2013-10-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003356

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003356, "Rituximab Plus Interleukin-2 in Treating Patients With Lymphoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00003356. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*